Developmental Outcomes
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Neurology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 12/6/2018 |
| Start Date: | November 2014 |
| End Date: | December 3, 2018 |
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE).
Determine whether the concentrations of UCH-L1 and GFAP measured in umbilical cord blood and
in blood 0-6 hours postnatal accurately predict the extent of neurodevelopmental deficits
and/or death at 18-20 months.
in blood 0-6 hours postnatal accurately predict the extent of neurodevelopmental deficits
and/or death at 18-20 months.
Children born with Hypoxic Ischemic Encephalopathy (HIE) and already enrolled in IRB
#504-2011 will be seen for a developmental follow-up at 18-20 months of age. The
developmental assessment tool that will be used is called the Bayley Scales of Infant and
Toddler Development: 3rd Edition (Bayley-III) Screening Test. The results of this test will
then be compared to the child's HIE biomarkers concentrations already obtained at birth.
#504-2011 will be seen for a developmental follow-up at 18-20 months of age. The
developmental assessment tool that will be used is called the Bayley Scales of Infant and
Toddler Development: 3rd Edition (Bayley-III) Screening Test. The results of this test will
then be compared to the child's HIE biomarkers concentrations already obtained at birth.
Inclusion Criteria:
- children already enrolled in IRB#504-2011
- 18-20 months of age
Exclusion Criteria:
We found this trial at
1
site
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
